New clinical trial registered: Inhibikase Therapeutics
@inhibikase
are initiating a Phase 2 study of their c-ABL inhibitor IkT-148009 in 120 individuals with untreated #Parkinsons; Safety & tolerability of 3 doses; 12-week study
New clinical trial registered: Inhibikase... - Cure Parkinson's
New clinical trial registered: Inhibikase Therapeutics are initiating a Phase 2 study of their c-ABL inhibitor IkT-148009
Read more about...
3 Replies
•
On no anti-parkinsonian drugs. Recruiting in Tampa, FL.
good news they plan to have several locations and the information will be on their website soon
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
Not what you're looking for?
You may also like...
A (minor) update by Inhibikase Therapeutics on their Phase 2 trial of Risvodetinib (IkT-148009) for Parkinson's Disease.
in the trial record].\\"...
Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs
https://www.inhibikase.com/news/press-releases/detail/66/inhibikase-therapeutics-announces-fda-clini
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
study in 400 individuals with LRRK2-associated #Parkinsons...
29% IMPROVEMENT in Alzheimer's using just 4 supplements in Phase 2 Clinical Study
---------------------------------------------
https://youtu.be/SWM5pyooBBg
Related Posts
The \"UP-study\" phase 2 trial of UDCA Co funded by Cure Parkinson's led by Prof Oliver Bandmann
AnnovisBio has initiated a 6-month Phase 3 study to evaluate 2 different doses Buntanetap (posiphen) in 450 participants with PD
Hope Biosciences Stem Cell Research Foundation- Get enrolled in the trial 
Dr. Milto Werner, Inhibikase 
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
